# Neuroprotectant for Hypertensive Intracerebral Hemorrhage

Study · id `cardio:ct-nct03546283` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03546283](<https://clinicaltrials.gov/study/NCT03546283>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03546283

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 422 participants.

## Technical summary

Registry record NCT03546283. Randomized; quadruple masking; primary purpose treatment. Start 2018-06-15 (anticipated); primary completion 2020-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 422 participants (planned count; ClinicalTrials.gov record NCT03546283, source copy `cardio:ctgov-nct03546283-2018-06-06`, retrieved 2026-10-31)
- Planned start: 2018-06-15 (anticipated) (ClinicalTrials.gov record NCT03546283, source copy `cardio:ctgov-nct03546283-2018-06-06`, retrieved 2026-10-31)
- Primary completion: 2020-07-31 (anticipated) (ClinicalTrials.gov record NCT03546283, source copy `cardio:ctgov-nct03546283-2018-06-06`, retrieved 2026-10-31)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT03546283, source copy `cardio:ctgov-nct03546283-2018-06-06`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT03546283, source copy `cardio:ctgov-nct03546283-2018-06-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03546283-2018-06-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Neuroprotectant for Hypertensive Intracerebral Hemorrhage
- Condition: Intracerebral Hemorrhage
- Intervention (Drug): Placebos
- Intervention (Drug): Cattle Encephalon Glycoside and Ignotin
- Lead sponsor: Rong Hu, MD
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)

## Provenance

Content hash: 763b9da1b7f284a0ffd6a83c62c5020482fd6b6e2b093873a5e5a3249589caef
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
